Guizhou Yibai Pharmaceutical Co. Ltd. Class A

Guizhou Yibai Pharmaceutical Co. Ltd. Class A

SSSE:600594
3.04
CNY
-0.06
(-1.94%)
-0.50EPS
2.86BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.86
3.99
4.17
4.66
4.8
4.9
4.25
4.32
4.23
3.45
3.57
2.76
2.37
1.8
Basic EPS, GAAP
0.59
0.6
0.24
0.49
0.49
-1.1
0.16
0.28
0.31
-0.55
0.13
-0.4
-0.42
-0.5
Free Cash Flow per Basic Share
0.42
0.43
0.36
0.06
0.35
-0.14
0.2
-0.04
0.61
0.03
0.31
-0.01
0.28
- -
Dividend per Share
0.11
0.11
0.12
0.09
0.15
0.16
0.08
0.69
0.19
0.06
0.05
0.11
0.04
0.04
Book Value per Share
2.67
4.33
4.51
4.98
5.34
4.18
4.34
4.03
4.21
3.61
3.64
3.14
2.76
2.6
Tangible Book Value per Share
1.79
1.82
2.02
1.9
2.16
2.62
2.87
2.8
2.75
2.95
3.02
2.57
2.37
2.21
Basic Weighted Avg Shares
721
792
792
792
793
792
791
791
791
793
789
789
785
783
Sales/Revenue/Turnover
2,785
3,157
3,303
3,687
3,808
3,883
3,361
3,413
3,347
2,735
2,821
2,174
1,863
1,406
Operating Margin (%)
19.58
17.55
7.81
14.43
14.18
9.4
9.82
14.71
14.99
9.85
8.62
-10.09
-5.02
-11.35
Depreciation Expense
46
82
86
113
139
179
153
141
150
181
201
193
171
- -
Net Income, GAAP
429
478
189
385
387
-874
128
220
244
-438
103
-317
-330
-394
Effective Tax Rate (%)
16.39
13.53
15.54
18.61
16.32
- -
43.06
31.94
25.64
- -
30.96
- -
- -
- -
Profit Margin (%)
15.41
15.15
5.73
10.44
10.16
-22.5
3.81
6.44
7.28
-16.01
3.67
-14.59
-17.69
-28.04
Working Capital
694
952
878
605
925
1,137
1,650
748
641
868
1,140
801
539
445
LT Debt
21
251
251
377
755
515
776
94
328
372
418
330
102
96
Total Equity
1,932
3,442
3,586
4,240
4,641
3,762
3,560
3,291
3,391
3,007
3,018
2,606
2,271
2,116
Return on Invested Capital (%)
19.05
13.43
3.66
7.2
6.38
- -
2.63
4.54
5.3
- -
2.34
- -
- -
- -
Return on Capital (%)
21.34
15.55
5.2
8.15
7.17
- -
3.28
5.66
6.45
- -
3.22
- -
- -
- -
Return on Common Equity (%)
24.79
17.87
5.41
10.25
9.47
-23.18
3.8
6.63
7.47
-14.14
3.6
-11.81
-14.09
-17.5

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
563
539
577
LT Borrowings
150
150
86
LT Finance Leases
2
- -
10
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
792
792
784
Market Capitalization
3,136
2,352
2,855

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,443
1,345
1,264
Cash, Cash Equivalents & STI
490
430
403
Accounts Receivable, Net
130
129
128
Inventories
540
526
495
Total Current Liabilities
848
792
818
Payables & Accruals
- -
- -
- -
ST Debt
563
539
577
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.86%
-6.89%
-12.87%
Free Cash Flow
-352.38%
-682.72%
-2,446.64%
Net Income, GAAP
-106.04%
-159.05%
3.89%
Sales/Revenue/Turnover
-4.93%
-10.87%
-14.31%
Total Cash Common Dividend
62.33%
-22.43%
-66.98%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
573
596
546
460
2,174
2025
501
492
- -
416
1,863
2026
359
331
301
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.09
-0.05
-0.08
-0.19
-0.4
2025
-0.01
-0.01
- -
-0.31
-0.42
2026
-0.04
-0.06
-0.09
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.08
0.01
0.01
0.11
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
0.01
0.01
- -
- -

Company Description

CEO
Ya Qi Dou
Full Time Employees
4,832
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 220-1, Baiyun Avenue Guiyang GZ China 550008
IPO Date
Mar 8, 2004
Website
gzcci.com
Business
Guizhou Yibai Pharmaceutical Co., Ltd. (600594.SS) researches, develops, produces and sells pharmaceutical products principally in China; the company engages in pharmaceutical industry, medical services and big health industry segments. It manufactures chemical drugs, traditional Chinese medicines and biological drugs in forms including capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, pills and oral solutions targeting tumor, cerebrovascular, respiratory, rheumatism, digestive, pediatric, gynecological, anti-infection, anti-inflammatory and analgesic therapeutic areas; key products encompass injectable loboplatin (10mg and 50mg), Aidi injection, ginkgo damole injection, compound cantharide capsules, Ximaitong capsules, Rikitong blood drop pills, Dandeng Yiyang capsules, gynecologic hemostatic granules, gynecologic menstrual relief pills, Ishirokang tablets, Jinlian purifying effervescent tablets and Keke family cough products. Medical services involve operation and management of comprehensive hospitals, tumor specialty hospitals and tumor radiotherapy centers such as Mianyang Fulian Hospital, Liaoyang Zhongao Hospital and Deyang Cancer Hospital; big health offerings feature Miao medicine-based products including candy, plant beverages and ointments. Founded in 1995 and headquartered at No. 220-1 Baiyun Avenue, Yunyan District, Guiyang, Guizhou, the company listed on the Shanghai Stock Exchange in 2004 as Guizhou's first private listed enterprise and employs around 5,260 people with domestic market focus. In August 2025, it announced acquisition of Guizhou Yibai Traditional Chinese Medicine Formula Granule Pharmaceutical Co Ltd for CNY 11.15 million to expand traditional Chinese medicine capabilities; recent developments include resumption of production and sales for pediatric cough syrups following regulatory notices and integration of AI models like DeepSeek for administrative, medical and GMP compliance applications.